SKYE MURRAY: Open Payments
NPI 1457641169 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$974 in 66 payments from 15 companies in 2025. Trend: 2023 $548 · 2024 $664 · 2025 $974
Food & beverage: $974
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $196 |
| Amgen Inc. | 12 | $169 |
| AstraZeneca Pharmaceuticals LP | 5 | $92 |
| Novo Nordisk Inc | 4 | $89 |
| Merck Sharp & Dohme LLC | 4 | $71 |
| Boston Scientific Corporation | 2 | $63 |
| BridgeBio Pharma, Inc. | 3 | $56 |
| PFIZER INC. | 2 | $45 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | 3 | $41 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
Products named: LEQVIO, REPATHA, VERQUVO, WATCHMAN Access System, Attruby, FARXIGA, Ozempic, Rybelsus.
Industry payments across NE — which companies pay providers there.
